Bristol/NCI extend Taxol CRADA; new agreement worth $30 mil. per year to NIH institute.
BRISTOL/NCI TAXOL AGREEMENT WORTH UP TO $30 MIL. PER YEAR to the institute, Bristol stated Dec. 4. Under the new agreement, Bristol-Myers Squibb has been granted exclusive worldwide rights to three National Cancer Institute inventions concerning Taxol (paclitaxel) for future development. Bristol and the NIH institute have also extended their Cooperative Research and Development Agreement for Taxol through December 1997. The CRADA was first signed in 1990.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth